IPM Take
This study strengthens the case for national precision oncology programmes, but it also puts a hard limit on the hype. Genomic testing does not automatically create better outcomes. Patients need evidence-ranked results, molecular tumour board interpretation, clinical trial access and reimbursement routes that can turn a genomic finding into an actual treatment decision. The message is clear: sequencing is only useful when the system is ready to act on high-confidence evidence.
Executive Summary
A JAMA Oncology cohort study assessed 3,383 adults with advanced solid tumours enrolled in Australia’s Molecular Screening and Therapeutic, MoST, precision oncology programme. Patients had rare or refractory advanced cancers and underwent comprehensive genomic profiling. Therapies were classified using the TOPOGRAPH evidence framework, which ranks biomarker-treatment matches by evidence strength. Patients with biomarkers supported by prospective trial evidence who received matched therapy had a median overall survival of 21.2 months, compared with 12.8 months for those receiving unmatched therapy. No comparable survival benefit was seen when matching was based only on investigational or repurposed evidence.
Why it matters
- Clinicians: Need evidence-ranked genomic interpretation, not just a sequencing report, to decide which findings are actionable.
- Payers / HTA bodies: Should distinguish between high-confidence biomarker-treatment matches and weaker exploratory matches when funding tests, therapies and trial access.
- Patients / advocates: Can use this evidence to push for genomic testing that is connected to real treatment access, not testing that ends with no pathway.
For years, precision oncology has promised to match the right patient to the right therapy. The problem is that not every genomic finding is equally actionable. Before programmes like MoST, a tumour alteration could create hope but also uncertainty: is this biomarker truly linked to benefit, or is it only biologically interesting?
The Australian study helps clarify that distinction. It used the TOPOGRAPH framework to rank biomarker-treatment matches by evidence strength. The clearest survival benefit appeared when the match was supported by prospective clinical trial evidence. Matches based on weaker exploratory evidence, or treatment repurposed from other cancer types, did not show the same benefit.
This matters politically because health systems are being asked to pay for broader genomic profiling, molecular tumour boards and targeted therapies, often for small or rare cancer populations. The study suggests that investment is most defensible when testing is connected to evidence-based treatment selection and clinical trial infrastructure.
For patients with rare and refractory cancers, the message is powerful but precise: genomic profiling can matter, but only if the system can act on the result. The next access question is not whether sequencing should expand. It is whether countries can build the evidence, referral and reimbursement machinery that lets eligible patients receive matched therapies before the treatment window closes.
